Abstract Throughout life, hematopoietic stem cells (HSCs) sustain the blood cell supply through their capacities for self-renewal and multilineage differentiation. These processes are regulated within a specialized microenvironment termed the 'niche'. Here, we show a novel mechanism for regulating HSC function that is mediated by nephroblastoma overexpressed (Nov/CCN3), a matricellular protein member of the CCN family. We found that Nov contributes to the maintenance of long-term repopulating (LTR) activity through association with integrin avb3 on HSCs. The resultant b3 integrin outside-in signaling is dependent on thrombopoietin (TPO), a crucial cytokine involved in HSC maintenance. TPO was required for Nov binding to integrin avb3, and stimulated Nov expression in HSCs. However, in the presence of IFNc, a cytokine known to impair HSC function, not only was TPO-induced expression of Nov suppressed, but the LTR activity was conversely impaired by TPO-mediated ligation of integrin avb3 with exogenous ligands, including Nov, as well.
Introduction
Hematopoietic stem cells (HSCs) are responsible for the life-long maintenance of the hematopoietic system both by sustaining HSCs through self-renewal and by giving rise to the various blood cell lineages via stepwise differentiation. To maintain this capacity, HSCs reside in a specialized microenvironment within the bone marrow (BM) termed a 'niche,' where their functions are appropriately regulated via complex combinations of mechanisms, including cytokine signaling, signaling via cell-cell contact, and cellextracellular matrix (ECM) adhesion [1] .
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We recently reported a novel mechanism of integrin avb3 outside-in signaling that is indispensable for the regulation of the long-term repopulating (LTR) activity of HSCs [2] . This integrin function was dependent on the presence of thrombopoietin (TPO), an essential cytokine that contributes to HSC maintenance [3] [4] [5] and promotes avb3 integrin activation (a conformational change increasing its ligand affinity) through induction of integrin inside-out signaling (a pathway that activates integrins in response to extracellular stimulation) [2] . These findings established a mechanistic link between integrin avb3 signaling and TPO in maintaining the LTR activity of HSCs.
Nephroblastoma overexpressed (Nov/CCN3) is a soluble factor that belongs to the CCN family and is reportedly involved in modulating several biological processes including cell proliferation, cell adhesion, wound healing, and angiogenesis, through association with integrins, including integrin avb3 [6] [7] [8] . Recently, human HSCs were reported to express higher Nov levels than other progenitor cells, suggesting that Nov expression may be a hallmark of HSCs [9, 10] . In addition, endogenous Nov expression in HSCs seems to be required for the maintenance of HSC function in vivo because the knockdown of Nov expression impaired the repopulating activity of human HSCs [9] . Furthermore, the addition of recombinant Nov was shown to enhance the repopulating activity of human HSCs cultured ex vivo [9] . These data suggest that Nov acts as a positive regulator of HSC function, however, the underlying mechanism by which Nov regulates HSC function remains unclear.
Interferon-c (IFNc) is a cytokine that modulates immune systems and inflammation. While IFNc reportedly promotes HSC proliferation in vivo by prompting dormant HSCs to enter the cell cycle, this response is accompanied by an impaired maintenance of LTR activity [11] . The negative regulation of LTR activity by IFNc is mediated through STAT1 activation. Another recent report showed that IFNc directly impairs the proliferative capacity of HSCs in vitro, thereby suppressing LTR activity [12] . It thus appears that IFNc contributes to the maintenance of hematopoietic homeostasis through negative regulation of HSC function.
In this study, we identify a novel mechanism through which Nov regulates murine HSC function. Nov functions as a ligand of integrin avb3 on HSCs, thereby contributing to the maintenance of LTR activity, which is dependent on TPO. In the presence of IFNc, however, the ligation of integrin avb3 with Nov or ECM exerts negative influences on HSC function. These findings demonstrate for the first time that Nov regulates HSC function via integrin avb3 in the presence of simultaneous stimulation by other cytokines.
Materials and methods

Animals
The animals used in this study are described in ''Supplemental Methods''.
Antibodies
The antibodies used in this study are described in ''Supplemental Methods''.
Cell sorting and flow cytometric analyses A MoFlo XDP or Gallios flow cytometer (Beckman Coulter Inc., Brea, CA) was used for cell sorting and flow cytometric analyses as described previously [2] .
Estimation of Nov binding on HSCs
CD34
-KSL HSCs were cultured in S-Clone SF-03 medium (Eidia Co., Ltd., Tokyo, Japan) supplemented with 0.5 % bovine serum albumin (Sigma-Aldrich Corporation, St. Louis, MO), 1 mM MnCl 2 (Wako Junyaku, Osaka, Japan), 50 ng/ml TPO (R&D Systems, Minneapolis, MN), and/or 5 ng/ml IFNc Shenandoah Biotechnology Inc., Warwick, PA) for either 1 or 18 h prior to treatment with 2 lg/ml recombinant mouse (rm)Nov tagged with oligohistidine (His-10) (R&D Systems) for 1 h. To identify bound rmNov, cultured cells were stained with an Alexa Fluor 647-conjugated mouse antibody recognizing the His-tag (AbD Serotec, Kidlington, UK). Subsequently, the stained cells were subjected to flow cytometric analyses after they were washed twice with PBS. For the inhibitory experiments, 200 lM of an Arg-Gly-Asp-Ser (RGDS) synthetic peptide (Life Technologies, Inc., Carlsbad, CA) or 50 lg/ml of antibodies against the integrins b3 or av were added to the culture media, 1 h prior to the addition of rmNov. The Arg-Gly-Glu-Ser (RGES) peptide (Life Technologies, Inc.), Hamster IgG, or Rat IgG served as controls. All antibodies were purchased from BioLegend (San Diego, CA) unless otherwise indicated.
HSC cultures
Sorted CD150
? CD34 -KSL HSCs were cultured for 5 days in S-Clone SF-03 serum-free medium supplemented with 50 ng/ml rmNov, 50 ng/ml mouse TPO, 50 ng/ml mouse SCF (R&D Systems), and/or 5 ng/ml mouse IFNc.
Vitronectin (VN)-coated plates were prepared as described previously [2] . Following ex vivo culture, the total cell numbers were quantified by phase contrast microscopy, and subjected to the following experiments.
Long-term competitive repopulation assays
Long-term competitive repopulation assays were performed as described previously [13] . Briefly, cultured HSCs together with 2 9 10 5 whole BM competitor cells were transplanted into lethally irradiated (10 Gy) C57BL/ 6-Ly5.2 or C57BL/6-Ly5.1 congenic mice. Twenty weeks after transplantation, donor cell chimerism in the recipient mice was analyzed by flow cytometry. Recipient mice with donor cell chimerism ([1.0 % for myeloid and B-and T-lymphoid lineages) were considered to be multilineagereconstituted mice.
Estimation of the number of retained HSCs after culture (limiting dilution assay) Samples containing 20, 40, 80, or 150 CD150
? CD34 -KSL HSCs were sorted into individual wells of a 96-well plate and cultured for 5 days under the indicated conditions. Subsequently, whole cultured cells from each well were used for the transplantation assays as described above. Twenty weeks after transplantation, the percentage of unreconstructed mice (negative mice) was determined and the number of primary CD150
? CD34 -KSL cells required to retain one cell with LTR activity after culture was estimated based on the Poisson distribution [14] .
Quantitative real-time RT-PCR Using 5,000 sorted cells from each sample, mRNA expression was analyzed by quantitative real-time RT-PCR as previously described [2, 13] . This procedure is described in detail in the ''Supplemental Methods''.
Analyses of STAT activation
After cytokine stimulation, the STAT5 or STAT1 activation levels were determined by flow cytometric analyses. This procedure is described in detail in the ''Supplemental Methods''.
Statistical analysis
The results are expressed as mean ± standard deviation (SD). Statistical significance between two groups was assessed by the unpaired Student's t test. P values \0.05 were considered significant.
Results
Nov contributes to the maintenance of the TPOdependent LTR activity of HSCs through integrin avb3
We previously demonstrated that outside-in signaling via integrin avb3 plays a key role in the maintenance of HSC LTR activity [2] . Because Nov is a known integrin avb3 ligand [6] , we hypothesized that Nov acts via integrin avb3 to regulate LTR activity. To address this possibility, we first confirmed that Nov associates with integrin avb3 using flow cytometric analyses of CD34
-KSL HSCs treated with His-tagged rmNov. By staining with an antibody recognizing the His-tag, enhanced binding of rmNov could be detected when HSCs were simultaneously treated with rmNov and Mn 2? , a known integrin activator [15] , whereas little binding of rmNov to HSCs was observed in the absence of Mn 2? (Fig. 1a) . In addition, the effect of Mn was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, an integrin avb3 recognition sequence, but not by the ArgGly-Glu-Ser (RGES) control peptide. Furthermore, an antiintegrin b3 blocking antibody [16, 17] recapitulated the inhibitory effect of the RGDS peptide on Mn 2? -dependent binding of rmNov to HSCs. These results indicate that Nov is capable of associating with integrin avb3 on HSCs, which is dependent on the activation of this integrin. We previously demonstrated that TPO contributes to the activation of integrin avb3 on HSCs through inside-out signaling [2] , suggesting that TPO may mediate the association between Nov and integrin avb3 on HSCs. To confirm this hypothesis, we examined whether rmNov binds to cultured HSCs in the absence or presence of TPO. Although treatment with TPO for 1 h had little influence on rmNov binding to HSCs (Fig. 1b) , extending the treatment with this cytokine to 18 h significantly enhanced rmNov ligation (Fig. 1c) . In addition, the effect of TPO was inhibited in the presence of blocking antibodies against either the b3 or av integrin subunits (Fig. 1c) [16, 18] . These results indicate that TPO enables the association between Nov and integrin avb3 on HSCs and suggest that TPO and/or outside-in signaling via the integrin avb3 are involved in the Nov-mediated regulation of LTR activity.
Initially, to confirm whether TPO is involved in regulation of HSC functions by Nov, we performed transplantation assays using HSCs incubated with or without rmNov in the presence of TPO or stem cell factor (SCF), an essential cytokine for HSC maintenance that acts independently of integrin avb3 [2] (Fig. 2a) . Twenty weeks after transplantation, HSCs cultured with rmNov in the presence of TPO showed greater chimerism than cells cultured in the presence of TPO alone (Fig. 2a) . In contrast, rmNov had no effect on the LTR activity of HSCs cultured in the presence of SCF (Fig. 2a) . These results indicate that the positive effect of Nov on LTR activity is dependent on the presence of TPO. In addition, after the culture with TPO, rmNov had no effect on the total cell number, or on the frequency of KSL and CD48 -KSL cells, which are the HSC/hematopoietic progenitor cell (HPC) fraction, or the HSC-enriched populations, respectively (Supplemental Fig. 1 ) [19] . Thus, Nov is not involved in HSC expansion, at least during ex vivo culture. Collectively, these results suggest that Nov positively regulates the LTR activity of The data represent the mean ± SD (**P \ 0.01, n = 3). In addition,
CD34
-KSL cells cultured for 1 h (b) or 18 h (c) were treated with His-tagged rmNov and subsequently treated with an antibody recognizing the His-tag before flow cytometric analyses as described above. Some cells were treated with the indicated antibodies during culture. Ham or Rat IgG was utilized as controls for the anti-b3 or av integrin antibodies, respectively. The histograms depict the fluorescence intensities of bound rmNov: white, cells cultured in the absence of cytokine; and gray, cells cultured in the presence of TPO. The graph depicts the relative MFI; the fluorescence intensity in the absence of cytokine served as a control. The data represent the mean ± SD (**P \ 0.01, n = 3)
individual HSCs, but it has no effect on HSC expansion. This behavior is reminiscent of the behavior of other integrin avb3 ligands [2] and strongly supports the hypothesis that Nov acts via integrin avb3 to regulate HSC function.
We have previously shown that outside-in signaling is indispensable for the sustained LTR activity mediated by b3 integrin [2] . Therefore, to directly confirm that outsidein signaling via integrin avb3 is crucial for the positive effect of Nov on LTR activity, we carried out transplantation assays using HSCs derived from b3 integrin Y747A knock-in mutant mice. In these mice, an alanine was substituted for tyrosine 747 in the b3 integrin subunit, thereby eliminating outside-in signaling [20] [21] [22] . We found that the positive effect of rmNov on LTR activity was almost completely lost in HSCs expressing the Y747A-mutated b3 integrin, even in the presence of TPO (Fig. 2b) . These data suggest that, such as TPO, outside-in signaling via integrin avb3 is indispensable for the Nov-mediated regulation of LTR activity. ? CD34 -KSL cells were cultured for 24 h with or without IFNc in the presence of TPO, and the expression of Nov mRNA was assessed using quantitative real-time RT-PCR. EGCG is an inhibitor of STAT1 activation. The graph depicts the levels of Nov mRNA expression normalized to the levels of B2m expression. The data represent the mean ± SD (**P \ 0.01, *P \ 0.05, n = 5). b CD34 -KSL cells were stimulated for 15 min with the indicated cytokines in the presence or absence of EGCG and STAT1 phosphorylation was analyzed by flow cytometry. The histograms depict the levels of STAT1 phosphorylation at Y701: white, isotype control; and gray, anti-STAT1 PY701 antibody. The graph depicts the relative mean fluorescence intensity (MFI). Samples stained with isotype control antibody served as controls for each condition. The data represent the mean ± SD (**P \ 0.01, n = 3) (Fig. 3a) . TPO treatment was also associated with STAT5 phosphorylation (Fig. 3b) . Furthermore, Lnk -/-HSCs, which display prolonged activation of STAT5 in response to TPO treatment (Fig. 3c ) [25] , exhibited enhanced Nov expression compared to Wt HSCs not only after treatment with TPO but also in vivo (Fig. 3d) . In contrast, HSCs cultured in the presence of SCF or under cytokine-free conditions do not express Nov and exhibit minimal STAT5 activation (Fig. 3a, b) . These data suggest that TPO enables the induction of Nov expression in HSCs likely through STAT5 activation, as predicted from the previous reports [23, 24] . Interestingly, although neither freshly isolated Wt nor Lnk -/-CD34 ? KSL HPCs expressed Nov, TPO treatment of HPCs in vitro induced Nov expression and STAT5 activation. These effects were more pronounced in Lnkdeficient HPCs (Fig. 4) . TPO thus appears to have the capacity to induce Nov expression in both HSCs and HPCs, suggesting that expression of Nov is dependent on external stimulation rather than the cell-autonomous phenotypes.
IFNc impairs the TPO-induced expression of Nov in HSCs through the activation of STAT1
In response to cytokine stimulation, activated STAT5 is reportedly recruited into IFNc-activated sequence (GAS) sites within the promoter region of Nov, and that this event correlates with Nov expression [23] . Because GAS sites were originally identified as STAT5 or STAT1 binding motifs that modulate IFNc-activated transcription [26] , we suspected that STAT1 was also involved in the regulation of STAT5-dependent Nov expression in HSCs. To test this possibility, we examined Nov expression in HSCs treated simultaneously with TPO and IFNc, a known inducer of STAT1 activation. We found that IFNc treatment impaired TPO-dependent Nov expression in both HSCs (Fig. 5a ) and HPCs (Data not shown). Moreover, the suppressive effect of IFNc was abrogated by treatment with epigallocatechin gallate (EGCG), an inhibitor of STAT1 activation (Fig. 5) [27]. Thus, the negative effect of IFNc on Nov expression in HSCs appears to be dependent on STAT1 activation, supporting the possibility that Nov expression is dependent on exogenous stimulation in both HSCs and HPCs.
Nov inhibits LTR activity via integrin avb3 in the presence of IFNc IFNc-mediated STAT1 activation reportedly leads to the suppression of HSC LTR activity as well as to an impaired HSC proliferation capacity in vitro [12] . Likewise, we confirmed that IFNc negatively affects both the proliferation capacity (Fig. 6a) and the LTR activity of HSCs cultured in the presence of TPO (Fig. 6b) . Our findings indicate that IFNc dominantly impairs TPO-dependent expression of Nov (Fig. 5a) , a positive regulator of LTR activity that may also be involved in the IFNc-mediated suppression of the repopulating activity of HSCs (Fig. 6b ) [9] . We therefore reasoned that the addition of rmNov to HSCs cultured in the presence of TPO likely prevented the IFNc-dependent impairment of LTR activity by both offsetting the IFNc-induced reduction in Nov expression and by acting as a positive regulator of LTR activity. To test this possibility, we performed transplantation assays using ? CD34 -KSL cells were cultured for 5 days with or without rmNov in the presence of TPO and IFNc. Afterward, the groups were individually transplanted as described above. The table shows the percentages of multi-lineage reconstituted mice. The numbers in parentheses denote multilineage reconstituted mice/tested mice. In addition, the percentages of unreconstructed mice (percentages of negative mice on the y axis) were plotted versus the numbers of primary CD150 HSCs cultured with or without rmNov in the presence of both TPO and IFNc Surprisingly, the addition of rmNov appeared to exert negative effects on both the proliferation capacity and the maintenance of HSCs, as evidenced by a decreased total cell number, suppressed chimerism and an increase in the percentage of unreconstructed mice (Fig. 6a, b) . To quantify the negative effects on HSC maintenance, we next performed a limiting dilution assay based on the transplantation assays. Consequently, this assay showed that approximately threefold the number of primary CD150 ? CD34 -KSL cells is required to retain one cell with LTR activity when cells are cultured in the presence of IFNc and treated with rmNov (Fig. 6c) . The number of HSCs decreased to approximately one-third compared with the control when cultured in the presence of IFNc and treated with rmNov (Fig. 6d) . Therefore, the suppressive actions of rmNov on cell proliferation (Fig. 6a) are less likely to contribute to its negative effects on HSC maintenance because they are insufficient to account for the decrease in the estimated HSC number after culture. Thus, these results indicate that Nov negatively affects the maintenance of LTR activity in the presence of IFNc, even when TPO is present. In addition, we confirmed that IFNc had little effect on the TPO-dependent association of rmNov with b3 integrin (Supplemental Fig. 2) , suggesting that integrin avb3 is also involved in the negative actions of Nov observed in the presence of IFNc. To confirm this hypothesis, we examined the IFNc-dependent effects of rmNov in HSCs derived from integrin b3 -/-mice. The addition of rmNov to integrin b3 -/-HSCs cultured in the presence of both TPO and IFNc had little effect on HSC proliferation (Fig. 6e) . Similarly, integrin b3 deficiency abolished the IFNc-dependent negative effects of rmNov on LTR activity that were observed in Wt HSCs (Fig. 6f) . Thus, such as its positive effects on HSC function in the presence of TPO, the negative effects of Nov in the presence of IFNc also appear to be mediated through integrin avb3.
Finally, we confirmed whether another integrin avb3 ligand had similar negative effects on HSC function in the presence of IFNc using HSCs cultured on plates coated with vitronectin (VN), a well-known integrin avb3 ligand. Although VN coating had little influence on the proliferative capacity of HSCs in the presence of IFNc Fig. 7a ), transplantation assays demonstrated that this ligand recapitulates the negative effects of rmNov on the maintenance of LTR activity (Fig. 7b-d) . These results strongly suggest a novel function of integrin avb3 that negatively affects HSC maintenance in the presence of IFNc.
Discussion
In this study, we demonstrate that Nov acts via integrin avb3 on HSCs to bidirectionally regulate LTR activity in vitro, which is dependent on TPO-dependent activation of this integrin as well as simultaneous stimulation by other cytokines (Fig. 8) . The observed positive effects of Nov on the maintenance of HSC LTR activity in the presence of TPO (Fig. 2a) are consistent with earlier findings [2, 9] , while our observation that Nov negatively affects LTR activity in the presence of IFNc (Fig. 6) is novel. The negative behavior of Nov in the presence of IFNc likely reflects a novel mechanism by which integrin avb3 regulates HSC function. Consistent with this possibility, VN, a well-known integrin avb3 ligand, also recapitulates the behavior of Nov in the presence of IFNc (Fig. 7) . Our findings thus provide a new understanding of the relationship between integrin and cytokine signaling in the regulation of HSC function.
Previously, Nov was thought to be exclusively expressed by HSCs in vivo and was thus considered a hallmark of those cells (Figs. 3a, 4) [9, 10] . However, our findings indicate that Nov expression does not seem to be an attribution of HSCs because Nov expression was evident in TPO-treated HPCs in vitro (Fig. 4) and SCF-treated cells lacking Nov expression were capable of engraftment (Figs. 2a, 3a) . In addition, our results indicate that Nov expression in HSCs and HPCs is strongly influenced by cytokine stimulation (Figs. 3, 4, 5) . These results suggest that the distribution of Nov expression in vivo is attributable to the environment surrounding each cell. Accordingly, we propose that TPO mediates Nov expression by HSCs in vivo because HSCs reportedly make contact with TPO-expressing cells within the osteoblastic niche [28] . Our data demonstrate that TPO supports both STAT5 activation and Nov expression in HSCs (Fig. 3) . Moreover, Nov expression in vivo was increased by Lnk deficiency, which causes prolonged TPO-dependent STAT5 activation (Fig. 3c, d ). These findings strongly suggest that TPO contributes to Nov expression in vivo. This possibility is also supported by a previous study showing that the positive effects of Lnk deficiency on the activation of JAK2, a signaling molecule that acts upstream of STAT5, are dependent on TPO stimulation but are unaffected by IL-3 or G-CSF [29] .
Although other cells that likely compose the HSC niche, such as osteoblasts and vascular endothelial cells, also express Nov [30, 31] , endogenous Nov expression in HSCs seems to have a stronger influence on the maintenance of HSC function within the BM niche because the knockdown of Nov expression in human HSCs leads to a decreased repopulating activity in vivo [9] . Indeed, this finding indicates that Nov secreted by the HSCs contributes to the maintenance of stem cell activity in vivo. Our findings demonstrate that TPO induces Nov expression in vitro (Fig. 3) , suggesting that TPO may regulate Nov expression in vivo. In addition, the positive effects of Nov on LTR activity in the presence of TPO seem to be mainly attributable to b3 integrin outside-in signaling (Fig. 2b) . Taken together, our findings suggest that endogenous Nov, along with external ligands, likely acts via avb3 integrin on HSCs to contribute to the maintenance of LTR activity within a TPO-enriched niche.
In the presence of IFNc, a cytokine that impairs HSC function, rmNov and VN exerted suppressive effects on HSC function in vitro, even in the presence of TPO (Figs. 6, 7) . These results imply that integrin avb3 ligands preferentially contribute to IFNc-dependent suppression of HSC function over TPO-dependent maintenance of LTR activity. Therefore, TPO-induced expression of Nov was impaired in HSCs treated with IFNc ( Fig. 5a ), which likely mediated the IFNc-dependent suppressive effects of avb3 integrin. Under similar conditions, exogenous ligands may give rise to integrin avb3-mediated suppression of LTR activity. However because IFNc seems to influence HSC regulation differently in vivo and in vitro [11, 12] , it remains unclear whether the IFNc-dependent effects of integrin ligands observed in vitro will be recapitulated in vivo. We also found that Nov, but not VN, suppressed HSC proliferation in the presence of IFNc (Figs. 6a, 7a ). This suppressive effect of Nov was dependent on the presence of IFNc, as rmNov had little effect on proliferation in the presence of TPO alone (Supplemental Fig. 1a) . Thus, the differential integrin avb3-mediated effects of Nov and VN on HSC function in the presence of IFNc may be attributable to their ligand specificity. Unlike VN, Nov is able to associate with surface antigens other than integrin receptors (e.g., Notch 1 and Connexin 43) [32, 33] , an ability that may contribute to its unique effects in the presence of IFNc. Our results also indicate that Nov associates with additional unidentified receptors on HSCs because the binding of rmNov to HSCs was not completely compromised by treatment with the anti-integrin antibodies (Fig. 1, Supplemental Fig. 2 ). These additional Nov ligations are not likely to exert a substantial effect on HSC functions because the effects of rmNov on HSCs were blocked by either b3 integrin deficiency (Fig. 6e, f) or the impairment of b3 integrin outside-in signaling (Fig. 2b) .
In conclusion, we have demonstrated a novel mechanism of Nov action on the regulation of HSC function. Our results show that TPO, IFNc integrin avb3, and Nov act in concert to regulate HSC function and shed light on the complex regulatory mechanisms governing HSC function within its BM niche. Our findings also expand on the Nov Fig. 8 A model depicting the regulation of Nov/integrin avb3-mediated maintenance of LTR activity of HSCs that requires simultaneous stimulation by other cytokines. a TPO is not only involved in HSC maintenance, but it also induces avb3 integrin activation (a conformational change that increases its ligand affinity). b Nov associates with the integrin avb3, thereby enhancing the TPOdependent maintenance of LTR activity that is mediated by b3 integrin outside-in signaling. c IFNc is capable of impairing the LTR activity of HSCs independently of the TPO-dependent activation of the avb3 integrin. d The presence of exogenous Nov induces b3 integrin-mediated signaling by acting in concert with IFNc rather than via TPO, resulting in further suppression of LTR activity results of our previous study, furthering our understanding of the relationship between integrin and cytokine signaling in HSCs and supporting our previously proposed model of the integrin avb3-mediated expansion of HSCs in vitro that does not negatively affect LTR activity [2] . Thus, this study provides a basis for further characterization of the HSC niche and for the development of in vitro methods of HSCs manipulation for transplantation purposes.
